相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
I. Tamaskar et al.
ANNALS OF ONCOLOGY (2008)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
David H. Garfield et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma
Edwin P. Rock et al.
ONCOLOGIST (2007)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine
J. W. B. de Groot et al.
ANNALS OF ONCOLOGY (2006)
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer:: a review
P. Schoffski et al.
ANNALS OF ONCOLOGY (2006)
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
F Baffert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Hypothyroidism in the elderly: Pathophysiology, diagnosis and treatment
P Laurberg et al.
DRUGS & AGING (2005)
Thyroid disease: pathophysiology and diagnosis
LM Demers
CLINICS IN LABORATORY MEDICINE (2004)
Subclinical thyroid disease - Scientific review and guidelines for diagnosis and management
MI Surks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week?
W Gartner et al.
THYROID (2004)
分享论文
